2型糖尿病患者に対する超速効型インスリン製剤を用いた bolus 単独療法12カ月後のアウトカム

概要

論文の詳細を見る
This study was conducted to investigate the long term outcome of mealtime dosings of a rapid-acting insulin analog on the morning fasting plasma glucose (FPG) and HbA1C levels in patients with type 2 diabetes. A rapid-acting insulin analog was administered at each mealtime to 90 Japanese patients with type 2 diabetes. The daily insulin dose was adjusted to achieve plasma glucose levels of 80-120 mg/d/ before lunch, dinner and bedtime, and was increased to the maximum dose needed to achieve the target glucose level. After 1 year of treatment at our out-patient clinic, 67 patients (76%) showed satisfactory glycemic control with this regimen; the FPG in these patients was 115±28 mg/d/ and the HbA1C was 6.5±1.1%, as compared with a FPG of 108±21 mg/d/ and HbA1C of 6.9±1.1% in the patients who required additional basal insulin replacement. Among the clinical characteristics at the time of hospitalization, only the BMI was found to predict the necessity of basal insulin replacement. Poor responses of insulin to glucagon and arginine may explain the failure of improvement of the FPG levels with postprandial insulin replacement alone. In approximately 80% of the patients with type 2 diabetes, the FPG and HbA1C levels were appropriately controlled with mealtime dosings of a rapid-acting insulin analog alone.
日本糖尿病学会 = Japan Diabetes Societyの論文
2007-06-30